Van Lanschot Kempen Investment Management N.V. Acquires 109,286 Shares of Johnson & Johnson (NYSE:JNJ)

Van Lanschot Kempen Investment Management N.V. increased its holdings in Johnson & Johnson (NYSE:JNJ) by 11.3% in the 4th quarter, Holdings Channel reports. The fund owned 1,074,408 shares of the company’s stock after buying an additional 109,286 shares during the quarter. Johnson & Johnson accounts for about 1.6% of Van Lanschot Kempen Investment Management N.V.’s investment portfolio, making the stock its 16th biggest position. Van Lanschot Kempen Investment Management N.V.’s holdings in Johnson & Johnson were worth $155,381,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of JNJ. Oregon Pacific Wealth Management LLC bought a new position in Johnson & Johnson in the 4th quarter worth about $949,000. Horan Securities Inc. raised its holdings in Johnson & Johnson by 1.3% in the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock worth $1,038,000 after buying an additional 90 shares during the last quarter. Strategic Financial Concepts LLC lifted its stake in shares of Johnson & Johnson by 57.9% in the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock worth $501,000 after buying an additional 1,271 shares in the last quarter. Lord Abbett & CO. LLC purchased a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $69,859,000. Finally, KPP Advisory Services LLC increased its position in shares of Johnson & Johnson by 4.7% during the fourth quarter. KPP Advisory Services LLC now owns 11,492 shares of the company’s stock valued at $1,662,000 after acquiring an additional 515 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on JNJ. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Bank of America decreased their target price on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, April 10th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Leerink Partners decreased their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $171.82.

Johnson & Johnson Stock Up 2.3 %

NYSE JNJ opened at $157.42 on Monday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $379.37 billion, a P/E ratio of 23.67, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. The stock’s 50-day moving average price is $159.49 and its 200-day moving average price is $154.95.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. On average, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.30%. The ex-dividend date of this dividend is Tuesday, May 27th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.